Background: Preventive approaches (including those related to care of long term central venous catheters, CVADs) and the incidence of bloodstream infections (BSI) in 2 German university affi liated paediatric oncology units. Patients and Methods: Non-interventional prospective observational study using the Oncoped surveillance module. Results: Center A included 85 patients in 31 months and Center B 84 patients in 21 months. The populations did not diff er in terms of age, gender, malignancy and disease status (fi rst illness vs. relapse). Center A used ports (46 %) and 2 diff erent Broviac catheters (54 %), in Center B nearly all patients with a CVAD had Broviacs (96 %). 30 BSI (24 patients) were diagnosed in Centre A and 28 BSI (22 patients) in Center B. Patients with relapsed malignancy experienced more BSI (51.4 % vs. 20.9 %; p = 0.001). Incidence rates were signifi cantly lower in Center A (3.47 vs. 7.93 BSI/1000 CVAD days; p = 0.037). Poisson regression analysis revealed a signifi cant lower incidence density (BSI/100 inpatient days) for all BSI in Center A (RR 0.47 CI95 0.27-0.81, p = 0.006). Overall, 52 % of all pathogens detected in blood cultures in Center A were Gram-positive (57 % in Center B) and 48 % Gram-negative (43 in Center B). One ALL patient without a CVAD died due to overwhelming sepsis caused by an ESBL-producing E. cloacae isolate. Conclusion: Paediatric cancer treatment centers diff er substantially in regard to management of CVADs and in other preventive strategies. The most important use of local surveillance data is longitudinal internal assessment in close cooperation with microbiology and hospital hygiene experts.
Introduction ▼
In paediatric patients with cancer, alterations in host defence mechanisms against infection are related to the underlying illness (e. g. haematologic malignancy), to intensive treatment with immunosuppressive drugs (neutropenia, lymphocytopenia), radiotherapy, surgical interventions, and to additional side eff ects such as gastrointestinal mucositis. In this setting, fever with or without neutropenia is an important complication [ 17 ] . Fever of unknown origin accounts for up to 60 % of all infections in addition to a wide spectrum of clinically or microbiologically defi ned infections. Bacteraemia due to Gram -positive and Gramnegative pathogens signifi cantly aff ects morbidity and even mortality in this high risk population [ 1 ] . Most patients with bacteraemia have a long term central venous access device (CVAD) in use. In paediatric cancer patients, the term 'CVAD' refers to tunnelled Broviac/Hickman or subcutaneously implanted Port catheters [ 1 , 21 , 25 ] . These devices are of proven benefi t for patients and caregivers but their use increases the risk of bacteraemia [ 11 ] . Paediatric cancer treatment centers still diff er substantially in approaching the management and care of CVADs. Unfortunately, it remains an unresolved issue, which combination ('bundle') of preventive strategies is eff ective in reducing CVAD-associated infection rates [ 23 ] . The prospective surveillance of bacteraemias with adapted case defi nitions and standardised methods for data analysis and reporting has been established in some German treatment centers as quality assurance initiative. Surveillance eff orts aim at the identifi cation of critical control points for the reduction of health-care associated infections in paediatric cancer patients [ 21 , 25 ] . Prospective surveillance data from diff erent participating units may be compared and used for benchmarking discussion ('share experiences and learn from the best') [ 8 ] . Herein, data derived from the prospective surveillance of all consecutive bacteraemias in 2 German treatment centers for paediatric patients with cancer is reported and compared. One aim of this report is to elucidate important diff erences in CVAD management and care in the corresponding units. This eventually leads to the discussion how local surveillance data about bacteraemias (with or without any association to the CVAD) may be used to improve patients' safety in the long term.
Methods ▼
To both university affi liated paediatric cancer treatment centers participating in this prospective surveillance study about 50 paediatric cancer patients are admitted per year with newly diagnosed or relapsed malignancies. Center A is a 16 bed and center B a 12 bed inpatient unit. Both centers run a specialised outpatient clinic in addition to inpatient facilities. Anticancer treatment of childhood malignancies refers to the cooperative protocols of the German Society for Paediatric Oncology and Haematology (GPOH). In patients with acute leukaemia, both centers adhere to protocols derived from the international BFM group. Fever was defi ned as body temperature > 38.5 °C for at least 4 h or once > 39 °C. Neutropenia was defi ned as a total number of granulocytes < 0.5 × 10 9 /L or a total number of leukocytes < 1.0 × 10 9 /L without diff erential counts available.
The comparative investigation of simultaneously sampled central and peripheral blood cultures in terms of diff erential time to positivity [ 9 ] adds to the early identifi cation of the CVAD as the probable source of bacteraemia [ 3 ] . Without simultaneous peripheral venous cultures up to 14 % of all positive blood cultures remain undetected [ 20 ] . In clinical practice, routine use of this technique is hampered by specifi c circumstances. First, patients and their parents are reluctant to tolerate additional pain and anxiety related to peripheral venous blood culture drawing in children with an easily accessible CVAD. This limits compliance with the corresponding diagnostic standard. Despite a written hospital-wide policy recommending the collection of additional peripheral blood cultures these are sampled in only 58 % of all cases in clinical practice [ 7 ] . Second, the practical impact of this procedure on the choice and duration of antibiotic treatment is negligible in most cases [ 3 ] . Supportive care recommendations published on behalf of the German Society for Paediatric Oncology and Haematology (GPOH) and the German Society for Paediatric Infectious Diseases (DGPI) do not recommend the additional collection of peripheral venous blood cultures from febrile paediatric cancer patients with a long term central venous catheter (CVAD) [ 3 , 13 , 23 ] . In this study, 2 blood culture samples (aerobic and anaerobic) were collected from patients with fever under aseptic conditions and after disinfection of the CVAD hub with isopropanole from the CVAD before the fi rst dose of intravenous antibiotics. Blood cultures were processed using the BD BACTEC™ automatic detection system (Beckton Dickinson, Heidelberg) and species diff erentiation according to standard microbiological procedures. Bacteremia (bloodstream infection; BSI) was defi ned as growth of a bacterial pathogen in blood culture derived from a patient with fever or other signs of infection. Patients with bacteremia and systemic infl ammatory response syndrome was allocated to the clinical severity grade 'sepsis' according to paediatric consensus criteria [ 10 ] . The same criteria were used for patients with growth of Candida spp. in blood cultures to diff erentiate Candidemia and Candida sepsis. At least 2 positive blood culture bottles were stipulated to accept coagulase-negative staphylococci (CoNS) as pathogens in this clinical context. 'CVAD-associated BSI' referred to a patient with BSI, a CVAD in use and no evidence of an alternative primary focus of infection. To allocate the BSI to the category 'CVADrelated infection' blood cultures taken from the device had to be subsequently positive for longer than 72 h or the bacteria were detected on the catheter tip after removal of the device. In case of patients with microbiologically or clinically defi ned primary focus of infection, the corresponding BSI was allocated as secondary bacteraemia. The prospective Oncoped tool for the surveillance of healthcare-related infections in paediatric cancer patients in Germany has been previously described in detail [ 21 , 24 , 25 ] . Incidence densities (BSI per 100 inpatient days) and incidence rates (BSI per 1000 CVAD utilization days) were calculated. Since the risk of CVAD related infection is highest during inpatient treatment (in particular in patients with ports) the Oncoped module uses inpatient CVAD utilization days as denominator [ 24 , 25 ] . This is an important diff erence to studies published by other groups [ 1 , 5 ] . In Center A, no selective decontamination of the gastrointestinal tract was performed because the attending paediatric oncologists were not convinced of the available evidence supporting its use [ 26 ] . In Center B, colistin was used for this purpose in highrisk patients (leukaemia, lymphoma, autologous stem cell transplantation). Downloaded by: Saarländische Universitäts-u. Landesbibliothek. Copyrighted material.
The study protocol was approved by the ethics committee of the medical faculty, University of Bonn and by the German Society of Infectious Diseases in Childhood (DGPI). Informed consent to participate in the collection and anonymized analysis of surveillance data was obtained according to institutional policies from patients or their parents.
The whole study population (n = 169 patients) was used to investigate the data for any correlation between basic patient charac- Table 3 shows the resulting infection rates. In Center A, the CVAD was removed during the course of the infection in 6 events (20 %), 1 deep port pocket soft tissue infection with secondary bacteraemia ( S. aureus ); 3 consecutive polymicrobial sepsis events in a single patient (see text below) and 2 CVAD-associated infections (no bacteria detected on the catheter tip) with persistent fever, 1 due to CoNS and 1 due to VRE, respectively. In Center B, 2 BSI (7 %) lead to early removal of the device: 1 CVAD-related BSI ( E. cloaecae ) as well as 1 secondary BSI event in which the CVAD was suspected, but not confi rmed as the primary source of P. aeruginosa bacteraemia. In Center B, none of the CVADs had to be removed prematurely due to a BSI caused by Gram-positive pathogens and persistent infection. The median duration of inpatient treatment related to the infection was 13 days (IQR 10-21 days; range, 7-80 days) in Center A and 8.5 days (IQR, 4-13 days; range, 3-28 days) in Center B (p = 0.03).
In Center A, 1 patient with severe haemophilia with factor VIII inhibitors experienced 3 consecutive polymicrobial BSIs, clinically presenting as septic shock events. This patient was included in the analysis, because he had previously received intensive immunosuppression with steroids, rituximab, cyclophosphamide and plasmapheresis. Host related reasons for this series of severe BSIs (severe combined acquired immunodefi ciency) and In both centers compared in our investigation, children, whose fever disappeared and who did not have additional risk factors for a complicated clinical course (e. g. mucositis, expected long lasting neutropenia for more than 10 days), received inpatient intravenous empiric antibiotic treatment of FUO for only 48 to 72 h. This approach is held to be safe and eff ective [ 16 ] . In both centers, the use of the glycopeptide teicoplanin was restricted to certain indications in order to limit its use in empirical treatment and to prevent the selection of Vancomycin-resistant Enterococci [ 28 ] .
Oral prophylaxis with non-absorbable antibiotics directed against aerobic Gram -negative Enterobacteriaceae (selective gut decontamination; SGD) has been proposed in early studies for patients with high risk ALL, high risk Non Hodgkin Lymphoma, AML induction treatment or after bone marrow transplantation [ 29 ] . Although used in practice in many centers, there is still no clear scientifi c evidence for the preventive effi cacy of SGD in paediatric cancer patients [ 12 ] . One group of paediatric oncologists from Liverpool, UK, recommended the use of SGD to prevent bacteraemias caused by P. aeruginosa [ 19 ] . Nonetheless, in their prospective study the proportion of Gramnegative BSIs due to P. aeruginosa (7.8 %) was in the same magnitude or even higher as in other centers which never use SGD [ 21 ] . In the study presented here, Colistin prophylaxis was not prospectively followed as a separate item in the surveillance module. Data considering Colistin prophylaxis from patients in center B had to be extracted from the patients' fi les retrospectively. Thus, it was not possible to reconsider the reasons in detail, why only a small proportion of eligible patients eventually received Colistin prophylaxis just before the event. We can only speculate whether this prophylaxis would have prevented Gram-negative BSIs. A recent international survey asked for supportive care practices for paediatric patients with AML [ 14 ] . Antibacterial prophylaxis was more common among Berlin-Frankfurt-Muenster institutions compared to Children's Oncology Group institutions (15/46, 33 % vs. 24/180, 13 %, P < 0.0001). The same authors investigated compliance issues related to anti-infective preventive measures in 216 children and adolescents [ 15 ] . Compliance rates were the highest for food restriction (89 %), the use of topic antimycotics (88 %) and cotrimoxazole for Pneumocystis jirovocii prophylaxis (87 %). Lower compliance rates were found for the use of face masks (69 %), antiseptic mouth rinses (67 %), nonabsorbable antibiotic agents (67 %), and restrictions in social contacts (66 %). The most frequent reasons for drug non-compliance were forgetfulness and patient refusal. Compliance issues have to be considered in any preventive strategy recommended during outpatient care and compliance is suspected to be low if bad tasting antimicrobial tablets or solutions have to be swallowed regularly by the patient. One interesting observation is the successful in situ treatment of all Gram-positive BSIs in Center B without premature removal of the CVAD. This argues for ethanol locking of Broviacs suspected to be the source of the infection [ 18 ] since this practice was routinely followed only in Center B.
Of outstanding practical importance is the observation of Gram-negative isolates resistant to fi rst line empirical treatment with Piperacillin-Tazobactam combined with Gentamicin or Tobramycin. Although such an ESBL-producing isolate was demonstrated only once in each center in blood culture the fatal outcome of one child with E. cloacae sepsis underlines the par-(fi rst diagnosis or relapsed malignancy) in the corresponding patient population. The practice of long term CVAD care diff ered substantially between both centers ( • ▶ Table 1 online).
There was no higher BSI rate in Center A compared to Center B despite important diff erences in catheter management. In Center A, CVADs were implanted prior to induction chemotherapy in children with acute lymphoblastic leukaemia (in contrast to the practice to postpone the CVAD implantation after day 33 in Center B) [ 11 ] . Intravenous administration sets were routinely changed after 7 days (compared to every 48 h in Center B) [ 27 ] and Broviacs were fl ushed only once a week (compared to twice a week in Center B). Only in Center A, a silver impregnated Broviac catheter (VYGON Lifecath™) was used in 30 of 84 patients with at least 1 CVAD (36 %). We did not fi nd a lower proportion of patients with at least one BSI in patients with a silver impregnated Broviac (data not shown), but our study was observational and in principal not meant to confi rm or exclude any signifi cant infl uence of the catheter material on infection rates. This would be subject to a diff erent study which, to our knowledge, is still awaited for paediatric cancer patients. The lower number and incidence rate of BSIs related to CoNS in Center A (without statistical signifi cance) may be related to the prophylactic use of a Taurolidine containing lock solution instead of heparin (100 E/ml sterile NaCl 0.9 %). One single center non randomized study using historical controls investigating this intervention in paediatric cancer patients confi rmed a signifi cant benefi t [ 22 ] . A prospective randomized single center study with taurolidine vs. heparin has recently been completed in Aarhus, Denmark. The publication of the results is awaited (Moller-Handrup M., Schroder H., personal communication). In general, Port catheters have a lower risk of CVAD-related bloodstream infections than Broviac catheters [ 2 ] . This may have been 1 cause of lower BSI rates in Center A. The choice of CVAD depends on the type of malignancy, the age of the patient, andto a signifi cant extend -on local clinical practice [ 2 , 21 ] . In contrast to our results, Cesaro et al. identifi ed the patients' age (< 4.7 years) as signifi cant predictor for premature removal of the CVAD [ 5 ] . In this Italian study, the overall rate of CVAD associated BSI was 0.44/1000 CVAD days but in-and outpatient CVAD utilisation days were used as denominator. This method of calculation leads to 'lower' incidence rates. The vast majority of non-elective removals in the Italian study were due to mechanical complications and not the consequence of CVAD-related infections. The same group compared 2 diff erent modalities of fl ushing central venous catheters in paediatric patients with cancer in 1 of the very few available prospective randomised studies [ 6 ] . During a 25-month study period 203 paediatric patients who had newly placed Broviac-Hickman CVC were randomly assigned to standard fl ushing with heparin solution (twice a week) or to fl ushing with normal saline via a positivepressure connecting device (experimental arm, once a week) [ 6 ] . A higher incidence of bacteremia was found in the experimental arm (incidence rate, 0.62 vs. 0.24/1000 CVAD days; P = 0.01). Nonetheless, the only factor signifi cantly associated with premature removal of a CVC was a diagnosis of leukaemia or lymphoma (HR, 2.3; CI95 1.1 to 4.7). Due to methodical limitations (e. g. fl ushing once vs. twice weekly; leaving the connecting device in place for 7 days, no details on local disinfection of the device, more patients with stem cell transplants in the experimental arm) it remains diffi cult to form tentative conclusions from this study. [ 17 ] . This extremely broad spectrum therapy may be deescalated and adjusted to in vitro sensitivity data as soon as the results of blood cultures and other diagnostic microbiological specimens become available [ 4 ] . Although the patient populations were comparable, our study revealed signifi cant variations in supportive care measures aiming at preventing bloodstream infections in the participating units. The complexity of the corresponding 'bundle approach' by the attending paediatric oncology team limits tentative conclusion on the preventive effi cacy of single components in particular in the long term care of CVADs. Therefore, it obviously does not make sense to use the data derived from prospective surveillance primarily for benchmarking between diff erent units by external observers [ 8 ] . The most important use of such standardised data on local infection rates is longitudinal internal assessment in close cooperation with experts from local microbiology and hospital hygiene and infection control facilities.
